Psychoactivity and abuse potential of sumatriptan
by
Sullivan JT, Preston KL, Testa MP,
Busch M, Jasinski DR
Department of Medicine,
Johns Hopkins University School of Medicine,
Baltimore, MD.
Clin Pharmacol Ther 1992 Dec; 52(6):635-42

ABSTRACT

Sumatriptan is a 5-HT1D agonist of therapeutic use in migraine and cluster headaches. To determine the profile of psychoactivity and abuse potential, a double-blind Latin-square crossover study was conducted in 12 male subjects with histories of substance abuse. The effects of subcutaneous placebo, sumatriptan (8 and 16 mg), and morphine (10 and 20 mg) were assessed on measures of subjective, behavioral, and physiologic responses including signs, symptoms, Addiction Research Center Inventory scales, onset of drug effects and miosis. Sumatriptan was psychoactive, was discriminated from placebo, produced a dose-related decrease on euphoria scores, elevated scores on measures of apathetic sedation and disliking, and lacked identification as a prototypic drug of abuse. There were no clinically significant effects on heart rate, pupil size, or blood pressure. In contrast, morphine (the positive control) produced expected dose-response relationships on measures of reinforcing and physiologic effects. The study suggests that sumatriptan has a low abuse potential.

TCAs
SSRIs
5-HT1
5-HT2
5-HT3
5-HT4
5-HT1a
5-HT1b
Triptans
Rizatriptan
Eltoprazine
Zolmitriptan
Knockout mice
5-HT2c/5-HT2b
MDMA and 5-HT1a
5-HT1b and reward
5-HT1b and anxiety
Aggression and serotonin
Triptans, migraine and depression
5-HT1d and melancholic depression
Sumitriptan (Imitrex, Imigran) for migraine

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family